Kymera Therapeutics (KYMR)
Develops oral protein degraders for immunology and partnered oncology programs.
Something off on this page? Send us feedback.
Develops oral protein degraders for immunological diseases through internal STAT6 and IRF5 programs, while Sanofi and Gilead advance partnered IRAK4 and CDK2 assets. Operates as a single development segment with no drug sales, relying on collaboration revenue and external funding to advance its pipeline.
Develops oral small-molecule medicines that use targeted protein degradation to remove disease-driving proteins. Its internal immunology pipeline centers on KT-621, a STAT6 degrader in mid-stage trials for atopic dermatitis and asthma, and KT-579, an IRF5 degrader in early clinical testing for autoimmune diseases.
Partnered programs include Sanofi-led KT-485/SAR447971, an IRAK4 degrader in early clinical testing for immuno-inflammatory diseases, and KT-200, a Gilead-partnered CDK2 molecular glue program for oncology. The discovery engine combines target selection, structural methods, proteomics, and translational biology to pursue proteins that conventional inhibitors struggle to address.
Runs research from Watertown and operates as a single development segment, with no drug sales and collaboration-based revenue. Clinical progress, regulatory approval, partner execution, outsourced trials, and external manufacturing remain structural dependencies.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 23, 2026 | Piper Sandler | Reiterate | Rating: —Target: $125 | Target: $140 |
| Sep 22, 2026 | Stifel Nicolaus | Target | Target: $114 | Target: $152 |
| Sep 10, 2026 | Wolfe Research | Upgrade | Target: $65 | Target: $180 |
| Aug 31, 2026 | Guggenheim | Reiterate | Rating: —Target: $135 | Target: $170 |
| Aug 6, 2026 | Morgan Stanley | Reiterate | Rating: —Target: $119 | Target: $135 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $691.0M · Total debt $82.2M · Total assets $1.65B · Shareholders' equity $1.51B
- Revenue
- $65.0M
- Operating income
- −$75.6M
- Net income
- −$61.2M
No dividends on record.
| Institutions | ≈ 116.89% | 97.19M shares | |
|---|---|---|---|
| 293 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 1.55% | 1.29M shares | |
| 9 holders · as of Sep 4, 2026 | |||
| Strategic holders | 0.38% | 318.9K shares | |
| 1 holder · as of Jun 26, 2026 | |||
| Adds to | 118.82% | ||
83.15M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 118.82%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
FMR LLCInstitution | 14.85% | 12.35M | as of Jun 30, 2026 |
Baker Bros. Advisors LPInstitution | 10.41% | 8.66M | as of Jun 30, 2026 |
Avoro Capital Advisors LLCInstitution | 8.99% | 7.47M | as of Jun 30, 2026 |
Price T Rowe Associates Inc /MD/Institution | 8.55% | 7.11M | as of Jun 30, 2026 |
T. Rowe Price Investment Management, Inc.Institution | 7.53% | 6.26M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 4, 2026 | Brian Adams | officer: Chief Legal Officer | −6,371 | $116.83 |
| Jul 7, 2026 | Nello Mainolfi | director, officer: Chief Executive Officer | −50,000 | $119.00 |
| Jun 29, 2026 | Bruce Booth | director | −153,300 | $108.05 |
| Jul 1, 2026 | Nello Mainolfi | director, officer: Chief Executive Officer | −80,000 | $115.29 |
| Jul 1, 2026 | Noah Goodman | officer: Chief Business Officer | −3,389 | $114.29 |
- Sanofi (ADR)
Dominates Type 2 inflammation through Dupixent
- Nurix Therapeutics
Direct degrader-platform overlap in STAT6 and IRAK4
- Regeneron
Co-owns the Dupixent benchmark for STAT6 biology
- Arvinas
Public PROTAC leader competing for degrader validation
- Monte Rosa Therapeutics
Molecular glue immunology peer with VAV1 and NEK7
- Eli Lilly
Challenges KT-621 in atopic dermatitis with Ebglyss
- C4 Therapeutics
Clinical TPD peer with TORPEDO and IRAK4 adjacency
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Kymera Therapeutics | $115.59 | −5.30% | $10.04B | — | — | 95.6 | +466.4% |
| Sanofi (ADR) | $41.60 | −2.14% | $102.08B | 76.0 | — | 1.8 | +11.2% |
| Nurix Therapeutics | $24.50 | −4.56% | $2.66B | — | — | 72.5 | −79.5% |
| Regeneron | $791.68 | −1.52% | $82.82B | 19.9 | 13.1 | 5.3 | +16.7% |
| Arvinas | $8.14 | −4.35% | $549.1M | 53.2 | — | 1.7 | +1,014.7% |
| Monte Rosa Therapeutics | $11.96 | −5.07% | $1.06B | — | — | 37.1 | −61.2% |
| Eli Lilly | $1,154.17 | −1.36% | $1.10T | 39.3 | 28.2 | 13.8 | +47.7% |
| C4 Therapeutics | $3.05 | −8.01% | $366.0M | — | — | 10.4 | +2.8% |
| Median | 46.2 | 20.6 | 10.4 | +11.2% |